Reading latest Pfizer PRDiscussing their new P2 Cachexia Cancer drug in a PR. Last call our dear Paul said that Egrifta was first and foremost a muscle builder, has been labeled many things before in light of the trend of the moment. But Thera did do a P2 trial in COPD wasting and failed because the patients were beyond repair I guess. That being said it could be an angle to partner on. I think Egrifta is contrindicated for Cancer patients but at that point this could be the last of their concern I suppose.